Salomon M. Stemmer

19.4k total citations · 2 hit papers
237 papers, 8.5k citations indexed

About

Salomon M. Stemmer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Salomon M. Stemmer has authored 237 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Oncology, 66 papers in Pulmonary and Respiratory Medicine and 41 papers in Cancer Research. Recurrent topics in Salomon M. Stemmer's work include Advanced Breast Cancer Therapies (33 papers), Cancer Treatment and Pharmacology (33 papers) and HER2/EGFR in Cancer Research (30 papers). Salomon M. Stemmer is often cited by papers focused on Advanced Breast Cancer Therapies (33 papers), Cancer Treatment and Pharmacology (33 papers) and HER2/EGFR in Cancer Research (30 papers). Salomon M. Stemmer collaborates with scholars based in Israel, United States and United Kingdom. Salomon M. Stemmer's co-authors include Irit Ben‐Aharon, Bella Kaufman, Georgeta Fried, Ora Rosengarten, Susan M. Domchek, Ayala Hubert, Ronnie Shapira‐Frommer, Judith Balmañà, Michael Friedländer and Gillian Mitchell and has published in prestigious journals such as Cell, JAMA and Nucleic Acids Research.

In The Last Decade

Salomon M. Stemmer

228 papers receiving 8.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation

2014 1.2k citations Bella Kaufman, Salomon M. Stemmer et al. Journal of Clinical Oncology profile →
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

2011 571 citations Salomon M. Stemmer et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Salomon M. Stemmer

Since Specialization

Citations

This map shows the geographic impact of Salomon M. Stemmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Salomon M. Stemmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Salomon M. Stemmer more than expected).

Fields of papers citing papers by Salomon M. Stemmer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Salomon M. Stemmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Salomon M. Stemmer. The network helps show where Salomon M. Stemmer may publish in the future.

Co-authorship network of co-authors of Salomon M. Stemmer

This figure shows the co-authorship network connecting the top 25 collaborators of Salomon M. Stemmer. A scholar is included among the top collaborators of Salomon M. Stemmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Salomon M. Stemmer. Salomon M. Stemmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A long‑term complete response to namodenoson in liver cancer with Child‑Pugh B cirrhosis: A case report 2024 ·Experimental and Therapeutic Medicine ·(unknown), Riccardo Lencioni, Salomon M. Stemmer, Motti Farbstein, (unknown), Avital Bareket‐Samish, Michael H. Silverman, Pnina Fishman	2
2	Mortality and Hospitalization Risk in Solid Organ Transplant Patients and SARS-CoV-2-Omicron Variant 2024 ·Transplantation ·(unknown), (unknown), Jonathan Ofer, (unknown), Salomon M. Stemmer, (unknown)	1
3	Interim analysis (IA) of the giredestrant (G) + everolimus (EVERO) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC). 2024 ·Journal of Clinical Oncology ·Seth A. Wander, Salomon M. Stemmer, Hope S. Rugo, Seock‐Ah Im, Peter K. H. Lau, Shani Paluch–Shimon, (unknown), (unknown), Mona D. Shah, Huy Ngo, Richard B. Schwab, Jing Zhu, Mafalda Oliveira	0
4	Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer 2024 ·Journal of Clinical Oncology ·Lajos Pusztai, (unknown), Kathy S. Albain, William E. Barlow, Salomon M. Stemmer, Allison Meisner, Gabriel N. Hortobágyi, Steven Shak, James M. Rae, Frederick L. Baehner, Priyanka Sharma, Kevin Kalinsky	1
5	Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry 2023 ·npj Breast Cancer ·Shlomit Strulov Shachar, Michelle Leviov, Rinat Yerushalmi, Karen Drumea, (unknown), Lior Soussan‐Gutman, Avital Bareket‐Samish, Amir Sonnenblick, (unknown), Ella Evron, Einav Nili Gal‐Yam, Shani Paluch–Shimon, Gil Bar‐Sela, Hadar Goldvaser, Salomon M. Stemmer	1
6	Tumor‐Targeted Poly(ArgGlyAsp) Nanocapsules for Personalized Cancer Therapy – In Vivo Study 2023 ·Advanced Therapeutics ·(unknown), (unknown), Ayelet Atkins, Avital Bareket‐Samish, Salomon M. Stemmer, Shlomo Margel, Neta Moskovits	2
7	161TiP A phase I/II, open-label study of an anti-ILT2 (LILRB1) antibody, SAR444881, administered alone and in combination with pembrolizumab, with or without chemotherapy, or cetuximab in patients with advanced solid tumors 2023 ·Immuno-Oncology Technology ·Ruth Perets, Salomon M. Stemmer, Ravit Geva, Talia Golan, Marwan Fakih, Justine V. Cohen, Christopher H. Lieu, Zhaohui Jin, (unknown), (unknown), (unknown), (unknown), (unknown), Raymond P. Perez, Mansi Agarwal, Giovanni Abbadessa, Ming‐Shiang Wu, Yi-Chan Lin, (unknown), Mitesh J. Borad	1
8	Proteinoid Polymers and Nanocapsules for Cancer Diagnostics, Therapy and Theranostics: In Vitro and In Vivo Studies 2023 ·Journal of Functional Biomaterials ·(unknown), Yuval Elias, Neta Moskovits, Salomon M. Stemmer, Shlomo Margel	5
9	Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study 2022 ·BMJ Open ·Noa Eliakim‐Raz, Amos Stemmer, (unknown), (unknown), (unknown), (unknown), Noam Erez, Avital Bareket‐Samish, Adva Levy‐Barda, Haim Ben‐Zvi, Neta Moskovits, Erez Bar‐Haim, Salomon M. Stemmer	4
10	Cancer-Associated Fibroblasts Promote Aggressive Gastric Cancer Phenotypes via Heat Shock Factor 1–Mediated Secretion of Extracellular Vesicles 2021 ·Cancer Research ·(unknown), Meirav Pevsner‐Fischer, Tal Goshen‐Lago, Judith Diment, Yaniv Stein, Hagar Lavon, Shimrit Mayer, Oshrat Levi-Galibov, Gil Friedman, Yifat Ofir‐Birin, Li-Jyun Syu, Cristina Migliore, Eyal Shimoni, Salomon M. Stemmer, Baruch Brenner, Andrzej A. Dlugosz, David Lyden, Neta Regev‐Rudzki, Irit Ben‐Aharon, Ruth Scherz‐Shouval	71
11	Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy 2021 ·Cancer Discovery ·Mario E. Lacouture, Zev A. Wainberg, Anisha B. Patel, Milan J. Anadkat, Salomon M. Stemmer, Einat Shacham‐Shmueli, Egmidio Medina, (unknown), (unknown), Antoni Ribas	16
12	Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer 2020 ·Annals of Oncology ·Hope S. Rugo, Fabrice André, Toshinari Yamashita, (unknown), I. Toledano, Salomon M. Stemmer, Josefina Cruz Jurado, Dejan Juric, Ingrid A. Mayer, Eva Ciruelos, Hiroji Iwata, Pierfranco Conté, Mario Campone, C. Wilke, David Mills, Agnes Lteif, Michelle C. Miller, (unknown), Sibylle Loibl	113
13	Pigment Epithelium–Derived Factor Alleviates Tamoxifen-Induced Endometrial Hyperplasia 2015 ·Molecular Cancer Therapeutics ·(unknown), Hadas Bar‐Joseph, Hadas Grossman, Noa Hasky, (unknown), Salomon M. Stemmer, Dana Chuderland, Ruth Shalgi, Irit Ben‐Aharon	10
14	Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer 2015 ·British Journal of Cancer ·Christoph Zielinski, István Láng, S. Beslija, Zsuzsanna Kahán, Moshe Inbar, Salomon M. Stemmer, (unknown), Damir Vrbanec, Diethelm Messinger, Thomas Brodowicz	21
15	Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses 2014 ·British Journal of Cancer ·Thomas Brodowicz, István Láng, Zsuzsanna Kahán, Richard Greil, S. Beslija, Salomon M. Stemmer, Bella Kaufman, Luboš Petruželka, Alexandru Eniu, (unknown), Krassimir Koynov, D. Vrbanec, Tadeusz Pieńkowski, Bohuslav Melichar, S. Špánik, (unknown), Diethelm Messinger, Moshe Inbar, Christoph Zielinski	24
16	Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer 2013 ·Journal of Clinical Oncology ·José Baselga, Patricia Gómez, Richard Greil, Sofía Braga, Miguel Ángel Climent, Andrew Wardley, Bella Kaufman, Salomon M. Stemmer, António Pêgo, Arlene Chan, J. Goeminne, Marie-Pascale Graas, Megan Kennedy, Eva María Ciruelos Gil, Andreas Schneeweiß, Angela Zubel, Jutta Groos, Helena Melezínková, Ahmad Awada	298
17	Tailoring Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Historical Prospective Study 2012 ·Chemotherapy ·Alona Zer, Shulamit Rizel, Rony Braunstein, Rinat Yerushalmi, Daniel Hendler, (unknown), (unknown), Aarón Sulkes, Salomon M. Stemmer	1
18	Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes 2010 ·Reproductive Toxicology ·Hadas Bar‐Joseph, Irit Ben‐Aharon, Shulamith Rizel, Salomon M. Stemmer, (unknown), Ruth Shalgi	76
19	CF102 an A3 adenosine receptor agonist induces in vivo apoptosis of Hepatocellular carcinoma 2008 ·Cancer Research ·(unknown), Salomon M. Stemmer, Lea Madi, David Castel, Avivit Ochaion, Shira Cohen, Faina Barer, (unknown), (unknown), Luis Del Valle, Pnina Fishman	0
20	Purging of Autologous Bone Marrow for Transplantation: The Protection and Selection of the Hematopoietic Progenitor Cell 1992 ·Journal of Hematotherapy ·Elizabeth J. Shpall, Salomon M. Stemmer, (unknown), L. Hami, (unknown), R. J. Berenson, (unknown)	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact